Point-of-care newborn SCD screening and early care in Côte d'Ivoire
Official title: Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
Run by Swiss Tropical & Public Health Institute · NCT07488520 · Data updated 2026-11-12
This trial tests whether using a Gazelle-Multispectral point-of-care test at birth plus early, comprehensive SCD care can reduce illnesses and deaths for babies with SCD in the first years of life.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 0 Months to 6 Months |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Swiss Tropical & Public Health Institute Academic / other |
| Locations | 2 sites (Abidjan and 1 other locations) |
| Status | Recruiting |
| Started | July 27, 2026 |
| Main results expected | December 2029 |
| Study ends | December 2029 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT07488520 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are infants aged 0–6 months identified at participating health facilities, born at or after 37 weeks gestation, not recently transfused, and whose guardians consent to participate.
✕Probably not a fit
Newborns with conditions not related to SCD or those with severe illness requiring emergency care at enrollment may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study in Yopougon, Côte d'Ivoire, evaluates a multifaceted approach that combines Gazelle-Multispectral point-of-care testing for newborns with early initiation of comprehensive SCD care. Participants are 0–6 months old and screen positive for SCD, followed by confirmatory testing and early treatment initiation. The study compares outcomes to historical regional data with attention to SCD-related illness, healthcare utilization for SCD-related events, and all-cause mortality over up to 3.5 years. Primary objectives include reducing SCD-related illnesses and healthcare-seeking events, and lowering death rates. The study is led by the Swiss Tropical and Public Health Institute, with local collaborators and sites in Yopougon, Abidjan.
Why it matters
Potential benefit: If successful, the approach could reduce SCD morbidity and mortality and improve access to early care for infants.
How similar studies have gone: Prior newborn SCD screening with early care has shown benefits in high-income settings; this trial extends the approach to a LMIC context and uses a POCT platform.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Children aged 0 - 6 months old identified at selected health facilities within the study area 2. Babies whose age plus the gestation period reaches 37 weeks or more 3. Children who did not receive a blood transfusion within the past 90 days 4. Children whose parents or guardians have consented to participate in the study by signing a consent form Exclusion Criteria: 1. Children already diagnosed with SCD 2. Children that are participating in another clinical research project 3. Children that are critically ill and require emergency treatment
Where it's running
-
Yopougon Millionnaire extension health center
Abidjan, Côte d’Ivoire Recruiting -
Yopougon SCD Center of Excellence
Yopougon, Côte d’Ivoire Not yet recruiting
Study contacts
- Study coordinator: Acellam Charles Abongomera, MD, MPH, PhD
- Email: charles.abongomera@swisstph.ch
- Phone: +41612848629
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sickle cell disease registry at Ain Shams University
This project creates an Ain Shams University registry of children and young people with sickle cell disease to track their health over time without providing a treatment.
-
Sickle Cell Kidney Sample Bank
This project will collect blood and urine from adults with sickle cell disease or sickle cell trait to see if linked samples and medical records can help researchers learn how kidney disease starts and progresses.
-
Comparing stem cell transplantation to disease-modifying therapy for children with sickle cell disease
This study is trying to see how well stem cell transplants work compared to other treatments for children with sickle cell disease over three years.
-
Examining megakaryocytes in patients with sickle cell disease
This study looks at how certain blood cells called megakaryocytes behave in people with sickle cell disease to see if they play a role in the complications of the illness.
-
Adjusting hydroxyurea dose using pharmacokinetics in children with sickle cell disease
This study tests whether using pharmacokinetic testing to guide hydroxyurea dosing helps kids with sickle cell disease reach the maximum tolerated dose faster than standard blood testing alone.
-
Depo-Provera (depot medroxyprogesterone acetate) for pain and biomarker changes in women with sickle cell disease
This study will test whether an injectable birth control (Depo-Provera) can reduce pain in adult women with sickle cell disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.